stockrow
Saturday 7 November 2026
Export ACRS’s income statement to Excel — free account
Aclaris Therapeutics, Inc.
ACRS Healthcare Biotechnology
Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024.
- Revenue
- −55.1%
- EPS
- 0.00%
- Free cash flow
- −119.9%
Quarter to September 2026, against a year earlier
3.88
0.27
+7.48%
Follow ACRS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
47.14 | 57.73 | 91.87 | 122.81 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(28.10) | (26.62) | (38.04) | (32.65) | |
P/B ratio |
3.58 | 3.36 | 6.06 | 4.71 | |
Price to Tangible BV |
3.84 | 3.53 | 6.42 | 4.92 | |
EV/Sales |
36.92 | 46.41 | 82.04 | 106.63 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.13) | (7.44) | (10.86) | (9.08) | |
EV/FCF |
(6.12) | (7.43) | (10.84) | (9.06) | |
Quick Ratio |
3.36 | 4.03 | 3.46 | 4.72 | |
Current Ratio |
3.36 | 4.03 | 3.46 | 5.09 | |
Net Debt/EBITDA |
4.01 | 4.77 | 3.79 | 5.38 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.04 | 0.04 | 0.04 | 0.03 | |
Operating CF/Net income |
0.66 | 0.92 | 0.92 | 1.30 | |
Capex/Depreciation |
(0.24) | (0.13) | (0.54) | (0.13) | |
Research and Development Expense of Revenue |
1,280.62% | 784.42% | 1,109.02% | 1,084.81% | |
Selling, General and Administrative Expense of Revenue |
430.58% | 337.83% | 371.27% | 407.70% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
225.95% | 160.22% | 164.03% | 203.85% | |
Graham Net Nets |
0.11 | 0.11 | 0.06 | 0.09 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(17.61%) | (14.93%) | (10.96%) | (11.03%) | |
Free Cash Flow Yield |
(12.80%) | (10.82%) | (8.23%) | (9.58%) | |
Revenue per Share |
0.01 | 0.02 | 0.01 | 0.01 | |
Operating CF per Share |
(0.11) | (0.14) | (0.14) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.11) | (0.14) | (0.14) | (0.16) | |
Cash per Share |
0.74 | 0.82 | 0.64 | 0.76 | |
Shareholders Equity per Share |
0.84 | 1.12 | 0.87 | 1.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.84 | 1.12 | 0.87 | 1.12 | |
Free Cash Flow |
(13.15) | (18.16) | (19.90) | (24.09) | |
Working Capital |
67.67 | 82.86 | 69.52 | 99.01 | |
Capital Expenditures |
(0.02) | (0.01) | (0.06) | (0.01) | |
Net Current Asset Value |
38.94 | 55.16 | 42.65 | 73.87 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.04 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.96 | 2.53 | 3.20 | — | |
Average Payables |
8.92 | 10.54 | 12.16 | 9.13 | |
Average Assets |
190.39 | 198.41 | 184.42 | 195.85 | |
Average Common Equity |
129.32 | 143.86 | 128.16 | 143.45 |
Columns are period end dates · fundamentals updated 5 Nov 2026